文献速递腹部技术与安全CTMRUSPET

胰腺神经内分泌肿瘤:2020年病理与影像表现及分类更新

Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification.
PubMed 文献 · Radiographics · 2020-08-14

胰腺神经内分泌肿瘤(panNENs)在临床、组织形态、遗传学及生物学行为上具有异质性,可伴发于多发性内分泌腺瘤病1型等遗传综合征。2017年WHO分类与第八版AJCC分期有重要更新,引入高分化高级别panNET这一新亚型,并与低分化panNEC区分。MDCT、MRI及内镜超声用于解剖定位与分期,生长抑素受体显像和18F-FDG PET/CT用于功能与代谢评估。

要点

  • panNENs按2010年WHO分类分为高分化panNET与低分化panNEC,新增高分化高级别panNET亚型。
  • 高分化高级别panNET与panNEC在发病机制、临床特征、影像表现、治疗及预后上为两种不同实体。
  • MDCT、MRI及内镜超声用于原发灶定位、局部侵犯与转移评估,生长抑素受体显像和18F-FDG PET/CT用于功能与代谢评估。

核心结论

  • 掌握panNENs在发病机制、分类与分期方面的最新更新及影像表现,有助于优化患者治疗。

研究设计与样本

  • 本文为Radiographics综述,系统总结panNENs的病理与影像表现及分类更新;原文未报告检索范围与纳入文献数量。

关键影像表现/征象

  • 功能性肿瘤因激素产生相关临床症状而早期表现,无功能性肿瘤常因占位效应而晚期表现。
  • 高达10%的panNENs发生于易患癌症的综合征患者,如多发性内分泌腺瘤病1型、von Hippel-Lindau病、结节性硬化复合征、神经纤维瘤病1型及胰高血糖素细胞腺瘤病。
  • panNENs按2010年WHO分类系统在组织病理学上分为高分化胰腺神经内分泌肿瘤(panNETs)或低分化胰腺神经内分泌癌(panNECs)。
  • 细胞遗传学与分子生物学进展显示panNECs存在显著异质性,并引入新肿瘤亚型——高分化高级别panNET。
  • 高分化高级别panNET与panNECs是两种不同实体,具有不同的发病机制、临床特征、影像表现、治疗选择及预后。

诊断标准与关键数值

  • 2010年WHO分类系统将panNENs组织病理学分为高分化panNETs与低分化panNECs。
  • 2017年WHO分类系统与第八版美国癌症联合委员会分期系统包含重大变更。
  • 原文未报告敏感度、特异度、AUC、阈值等诊断效能数值。

临床应用与阅片要点

  • 多排CT、MRI及内镜超声有助于原发肿瘤的解剖定位、局部区域范围及转移评估。
  • 生长抑素受体显像与氟18-氟脱氧葡萄糖PET/CT有助于功能与代谢评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Pancreatic neuroendocrine neoplasms (panNENs) are heterogeneous neoplasms with neuroendocrine differentiation that show characteristic clinical, histomorphologic, and prognostic features; genetic alterations; and biologic behavior. Up to 10% of panNENs develop in patients with syndromes that predispose them to cancer, such as multiple endocrine neoplasia type 1, von Hippel-Lindau disease, tuberous sclerosis complex, neurofibromatosis type 1, and glucagon cell adenomatosis. PanNENs are classified as either functioning tumors, which manifest early because of clinical symptoms related to increased hormone production, or nonfunctioning tumors, which often manifest late because of mass effect. PanNENs are histopathologically classified as well-differentiated pancreatic neuroendocrine tumors (panNETs) or poorly differentiated pancreatic neuroendocrine carcinomas (panNECs) according to the 2010 World Health Organization (WHO) classification system. Recent advances in cytogenetics and molecular biology have shown substantial heterogeneity in panNECs, and a new tumor subtype, well-differentiated, high-grade panNET, has been introduced. High-grade panNETs and panNECs are two distinct entities with different pathogenesis, clinical features, imaging findings, treatment options, and prognoses. The 2017 WHO classification system and the eighth edition of the American Joint Committee on Cancer staging system include substantial changes. Multidetector CT, MRI, and endoscopic US help in anatomic localization of the primary tumor, local-regional spread, and metastases. Somatostatin receptor scintigraphy and fluorine 18-fluorodeoxyglucose PET/CT are helpful for functional and metabolic assessment. Knowledge of recent updates in the pathogenesis, classification, and staging of panNENs and familiarity with their imaging findings allow optimal patient treatment. ©RSNA, 2020.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Khanna L, Prasad SR, Sunnapwar A, et al. Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification. Radiographics. 2020. PMID: 32795239. doi:10.1148/rg.2020200025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。